Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK104 plus lenvatinib versus lenvatinib in advanced hepatocellular carcinoma after failure of atezolizumab + bevacizumab
CTR20252142Phase 2Active
- Sponsor
- Akeso, Inc.
- Start
- Sep 2025
- Modality
- Small Molecules, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in hepatocellular carcinoma (HCC) comparing Cadonilimab + lenvatinib with Lenvatinib (2 arms). Primary endpoint: Objective response rate. Started Sep 2025; status: active.
02
Drugs
cadonilimablenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20252142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252142.